Literature DB >> 26459894

Large Cohort Study of Central Venous Catheter Thrombosis during Intravenous Antibiotic Therapy.

Stéphanie Guillet1, Valérie Zeller2, Vincent Dubée1, Françoise Ducroquet3, Nicole Desplaces4, Marie Hélène Horellou5, Simon Marmor6, Jean Marc Ziza7.   

Abstract

The frequency and risk factors for central venous catheter-related thrombosis (CRT) during prolonged intravenous (i.v.) antibiotic therapy have rarely been reported. The primary objective of this study was to evaluate the frequency, incidence, and risk factors for CRT among patients being treated with prolonged i.v. antibiotic therapy. The secondary objective was to describe the clinical manifestations, diagnostic evaluation, and clinical management. This cohort study was conducted between August 2004 and May 2010 in a French referral center for osteoarticular infections. All patients treated for bone and joint infections with i.v. antimicrobial therapy through a central venous catheter (CVC) for ≥2 weeks were included. Risk factors were identified using nonparametric tests and logistic regression. A case-control study investigated the role of vancomycin and catheter malposition. A total of 892 patients matched the inclusion criteria. CRT developed in 16 infections occurring in 16 patients (incidence, 0.39/1,000 catheter days). The median time to a CRT was 29 days (range, 12 to 48 days). Local clinical signs, fever, and secondary complications of CRT were present in 15, 8, and 4 patients, respectively. The median C-reactive protein level was 95 mg/liter. The treatment combined catheter removal and a median of 3 months (1.5 to 6 months) of anticoagulation therapy. The outcome was good in all patients, with no recurrence of CRT. Three risk factors were identified by multivariate analysis: male sex (odds ratio [OR], 5.4; 95% confidence interval [CI], 1.1 to 26.6), catheter malposition (OR, 5.3; 95% CI, 1.6 to 17.9), and use of vancomycin (OR, 22.9; 95% CI, 2.8 to 188). Catheter-related thrombosis is a rare but severe complication in patients treated with prolonged antimicrobial therapy. Vancomycin use was the most important risk factor identified.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26459894      PMCID: PMC4704170          DOI: 10.1128/AAC.00700-15

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  27 in total

Review 1.  2008 SOR guidelines for the prevention and treatment of thrombosis associated with central venous catheters in patients with cancer: report from the working group.

Authors:  P Debourdeau; D Kassab Chahmi; G Le Gal; I Kriegel; E Desruennes; M-C Douard; I Elalamy; G Meyer; P Mismetti; M Pavic; M-L Scrobohaci; H Lévesque; J M Renaudin; D Farge
Journal:  Ann Oncol       Date:  2009-06-12       Impact factor: 32.976

2.  [Symptomatic thrombosis in central venous catheter in oncology: a predictive score?].

Authors:  F Morazin; I Kriegel; B Asselain; M C Falcou
Journal:  Rev Med Interne       Date:  2005-01-05       Impact factor: 0.728

Review 3.  Management of occlusion and thrombosis associated with long-term indwelling central venous catheters.

Authors:  Jacquelyn L Baskin; Ching-Hon Pui; Ulrike Reiss; Judith A Wilimas; Monika L Metzger; Raul C Ribeiro; Scott C Howard
Journal:  Lancet       Date:  2009-07-11       Impact factor: 79.321

Review 4.  [Outpatient parenteral antimicrobial therapy (OPAT) in bone and joint infections].

Authors:  T Galpérine; F Ader; P Piriou; T Judet; C Perronne; L Bernard
Journal:  Med Mal Infect       Date:  2006-03-31       Impact factor: 2.152

5.  Continuous cefazolin infusion to treat bone and joint infections: clinical efficacy, feasibility, safety, and serum and bone concentrations.

Authors:  Valérie Zeller; Frédérick Durand; Marie-Dominique Kitzis; Luc Lhotellier; Jean-Marc Ziza; Patrick Mamoudy; Nicole Desplaces
Journal:  Antimicrob Agents Chemother       Date:  2008-12-15       Impact factor: 5.191

6.  Adverse effects of parenteral antimicrobial therapy for chronic bone infections.

Authors:  C Pulcini; T Couadau; E Bernard; A Lorthat-Jacob; T Bauer; E Cua; V Mondain; R-M Chichmanian; P Dellamonica; P-M Roger
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-09-26       Impact factor: 3.267

7.  Continuous clindamycin infusion, an innovative approach to treating bone and joint infections.

Authors:  Valérie Zeller; Arnaud Dzeing-Ella; Marie-Dominique Kitzis; Jean-Marc Ziza; Patrick Mamoudy; Nicole Desplaces
Journal:  Antimicrob Agents Chemother       Date:  2009-10-19       Impact factor: 5.191

Review 8.  Thrombotic and infectious complications of central venous catheters in patients with hematological malignancies.

Authors:  R S Boersma; K-S G Jie; A Verbon; E C M van Pampus; H C Schouten
Journal:  Ann Oncol       Date:  2007-10-24       Impact factor: 32.976

Review 9.  Thromboprophylaxis for patients with cancer and central venous catheters: a systematic review and a meta-analysis.

Authors:  Elie A Akl; Ganesh Kamath; Victor Yosuico; Seo Young Kim; Maddalena Barba; Francesca Sperati; Deborah J Cook; Holger J Schünemann
Journal:  Cancer       Date:  2008-06       Impact factor: 6.860

Review 10.  Catheter-associated thrombosis in patients with malignancy.

Authors:  Sudeep P Shivakumar; David R Anderson; Stephen Couban
Journal:  J Clin Oncol       Date:  2009-09-08       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.